WilmerHale Counsels Syros Pharmaceuticals in $35M Private Placement

WilmerHale Counsels Syros Pharmaceuticals in $35M Private Placement

Firm News

Syros Pharmaceuticals, a biopharmaceutical company pioneering the discovery and development of medicines to control the expression of disease-driving genes, announced that it has entered into a stock purchase agreement with several institutional accredited investors for the private placement of 2,592,591 shares of common stock at a purchase price of $13.50 per share, yielding expected gross proceeds of $35 million.

The WilmerHale team counseling Syros included Steven Singer, Cynthia Mazareas, Mhairi Immermann, and Killian Nolan.

Read Syros Pharmaceuticals' press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.